Low dose MTX for progressive neuro-Behçet's disease. A follow-up study for 4 years.
Kikuchi
Hirotoshi
H
Rheumatic Disease Division, Department of Internal Medicine, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan.
Aramaki
Kaori
K
Hirohata
Shunsei
S
D000328:Adult; D000368:Aged; D001528:Behcet Syndrome / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D003704:Dementia / Q000209:etiology; D018450:Disease Progression; D016903:Drug Monitoring; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015850:Interleukin-6 / Q000134:cerebrospinal fluid; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D010291:Paresis / Q000209:etiology; D013997:Time Factors; D014888:Wechsler Scales
D007166:Immunosuppressive Agents; D015850:Interleukin-6; D008727:Methotrexate